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Abstract Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with
abnormal progenitor self-renewal and defective white blood cell differentiation. Its pathogenesis
comprises subversion of transcriptional regulation, through mutation and by hijacking normal
chromatin regulation. Kat2a is a histone acetyltransferase central to promoter activity, that we
recently associated with stability of pluripotency networks, and identified as a genetic vulnerability
in AML. Through combined chromatin profiling and single-cell transcriptomics of a conditional
knockout mouse, we demonstrate that Kat2a contributes to leukemia propagation through
preservation of leukemia stem-like cells. Kat2a loss impacts transcription factor binding and
reduces transcriptional burst frequency in a subset of gene promoters, generating enhanced
variability of transcript levels. Destabilization of target programs shifts leukemia cell fate out of
self-renewal into differentiation. We propose that control of transcriptional variability is central to
leukemia stem-like cell propagation, and establish a paradigm exploitable in different tumors and
distinct stages of cancer evolution.
Introduction
Acute Myeloid Leukemia (AML) is the most prevalent leukemia in adults with a dismal prognosis of
less than 30% 5 year survival (Do¨hner et al., 2017). It is a heterogeneous disease, clinically and path-
ologically, with common cellular themes of myeloid differentiation block, and recurrent molecular
targeting of chromatin and transcriptional regulators. Effects on chromatin and transcription are
reflected in the AML mutational spectrum (Ley et al., 2013), as well as through the implication of
general chromatin regulators in AML pathogenesis, in the absence of specific mutation events
(Roe and Vakoc, 2013). Specific examples of AML dependence on unmutated chromatin regulators
include BRD4 (Dawson et al., 2011; Zuber et al., 2011), LSD1 (Harris et al., 2012) or DOT1L
(Bernt et al., 2011; Daigle et al., 2011), their importance highlighted by the fact that chemical
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inhibitors developed to target these regulators have progressed to clinical trials (Gallipoli et al.,
2015). More recently, TAF12, a component of the basal transcription factor complex TFIID, was
shown to be critical for AML cell maintenance through regulation of protein stability and activity of
the transcription factor MYB (Xu et al., 2018).
In a recent CRISPR drop-out screen of genetic dependencies in AML, we have identified several
members of the promoter-bound histone acetyl-transferase SAGA complex, including acetyl-trans-
ferase KAT2A, as being required for AML maintenance (Tzelepis et al., 2016). KAT2A was sug-
gested to impact cell survival and differentiation status, but its precise molecular mechanisms of
action remain to be elucidated, and it is unclear whether it is required in AML initiation, as well as
maintenance. Kat2a is a mammalian orthologue of yeast histone acetyl-transferase Gcn5, and is
required for H3K9 acetylation (H3K9ac) (Jin et al., 2014), a modification that fine-tunes, rather than
initiates, locus-specific transcriptional activity. Kat2a is required for specification of mesodermal
derivatives during early embryonic development (Lin et al., 2007; Wang et al., 2018), and for sur-
vival of neural stem and progenitor cells (Martı´nez-Cerden˜o et al., 2012). Loss of Kat2a in the
hematopoietic system from an early developmental stage did not grossly impact blood formation in
vivo, but could promote terminal granulocyte differentiation in vitro, through relief of protein acety-
lation-dependent inactivation of transcription factor Cebpa (Bararia et al., 2016). Nevertheless,
detailed testing of Kat2a contribution to hematopoietic stem and progenitor cell function is still
lacking.
Yeast Gcn5 is a classical regulator of transcriptional noise (Raser and O’Shea, 2004), with dele-
tion mutants enhancing cell-to-cell variability in gene expression measured across a range of locus
fluorescence reporters (Weinberger et al., 2012). Transcriptional noise reflects the variability in the
number of mRNA molecules produced from a given locus through time; snapshot studies of gene
expression capture the same phenomenon as cell-to-cell transcriptional heterogeneity
eLife digest Less than 30% of patients with acute myeloid leukaemia – an aggressive cancer of
the white blood cells – survive five years post-diagnosis. This disease disrupts the maturation of
white blood cells, resulting in the accumulation of immature cells that multiply and survive but are
incapable of completing their maturation process. Amongst these, a group of cancer cells known as
leukemic stem cells is responsible for continually replenishing the leukaemia, thus perpetuating its
growth.
Cancers develop when cells in the body acquire changes or mutations to their genetic makeup.
The mutations that lead to acute myeloid leukaemia often affect the activity of genes known as
epigenetic regulators. These genes regulate which proteins and other molecules cells make by
controlling the way in which cells ‘read’ their genetic instructions.
The epigenetic regulator Kat2a is thought to ‘tune’ the frequency at which cells read their genetic
instructions. This tuning mechanism decreases random fluctuations in the execution of the
instructions cells receive to make proteins and other molecules. In turn, this helps to ensure that
individual cells of the same type behave in a similar way, for example by keeping leukaemia cells in
an immature state. Here, Domingues, Kulkarni et al. investigated whether interfering with Kat2a can
make acute myeloid leukaemia less aggressive by allowing the immature white blood cells to
mature.
Domingues, Kulkarni et al. genetically engineered mice to remove Kat2a from blood cells on
demand and then inserted a mutation that causes acute myeloid leukaemia. The experiments
showed that the loss of Kat2a delayed the development of leukaemia in the mice and progressively
depleted leukaemia stem cells, causing the disease to become less aggressive. The results also
showed that loss of Kat2a caused more fluctuations in how the white blood cells read their genetic
code, which resulted in more variability in the molecules they produced and increased the tendency
of the cells to mature.
These findings establish that loss of Kat2a causes leukaemia stem cells to mature and stop
multiplying by untuning the frequency at which the cells read their genetic instructions. In the future,
it may be possible to develop drugs that target human KAT2A to treat acute myeloid leukaemia.
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(Sanchez et al., 2013). Transcriptional noise can result from the bursting nature of gene expression
(Chubb and Liverpool, 2010). Most if not all loci, undergo bursts of transcriptional activity with char-
acteristic frequency and size: burst frequency corresponds to the rate at which promoters become
engaged in active transcription; burst size measures the number of mRNA molecules produced dur-
ing each transcriptional burst (Cai et al., 2006). Both parameters contribute to mean gene expres-
sion, whereas transcriptional noise is more strictly dependent and shown to be anti-correlated with
burst frequency (Hornung et al., 2012). In yeast, size and frequency of bursts are increased through
histone acetylation of gene bodies and promoters, respectively (Weinberger et al., 2012).
In functional terms, transcriptional noise has been directly implicated as a mechanism of cell fate
choice in yeast (Blake et al., 2006) and bacteria (Su¨el et al., 2006), and recurrently associated, albeit
correlatively, with cell fate transitions in some mammalian systems (Moris et al., 2016). We had pre-
viously shown that normal transitions into hematopoietic lineage specification associate with cell-to-
cell transcriptional heterogeneity (Pina et al., 2012; Teles et al., 2013). More recently, we have
inhibited the activity of Kat2a in mouse embryonic stem cells, and observed an increase in transcrip-
tional heterogeneity that impacted the stability of pluripotency with rewiring of correlation gene reg-
ulatory networks (GRNs) (Moris et al., 2018). Whilst we have not mechanistically linked enhanced
heterogeneity with loss of pluripotency, we did observe propagation of variability of transcriptional
levels through the GRNs, downstream of nodes with differential H3K9ac.
Cancer, and in particular leukemia, can be perceived as a pathogenic imbalance of cell fate
choices, with maintained self-renewal and reduced exit into differentiation. We postulated that
enhancing transcriptional variability in AML cells, as may be achieved through Kat2a depletion,
would enhance the probability of differentiation cell fate transitions. By using a retroviral-delivered
MLL-AF9 model of AML in a conditional Kat2a knockout background, we show that loss of Kat2a
depletes AML stem-like cells, imposing a mild delay to disease initiation and severely impairing AML
propagation. At a molecular level, these changes are accompanied by specific loss of H3K9 acetyla-
tion at a subset of promoters, with reduced transcription factor binding and frequency of bursting,
and associated variability in transcriptional levels. Affected loci encode for general mitochondria and
nucleic acid metabolism, including translation, suggesting that they may contribute to cancer fate
decisions more generally, rather than in a disease-specific manner.
Results
Inducible loss of Kat2a in adult mouse hematopoiesis
In order to investigate the impact of Kat2a loss on self-renewal vs. differentiation of AML stem-like
cells (AML-SC), we generated an inducible conditional Kat2aFl/Fl KO mouse model and transformed
Kat2a excised (KO) and non-excised (WT) bone marrow (BM) cells through retroviral delivery of an
MLL-AF9 fusion transcript. This strategy allows for cellular and molecular investigation of Kat2a
requirements during transformation, whilst minimizing putative confounding effects of acquired
mutations on heterogeneity of transcription, such as might be observed in established human or
mouse AML. The choice of a strong oncogenic event such as MLL-AF9 (Ley et al., 2013;
Krivtsov et al., 2006; Somervaille and Cleary, 2006) minimizes the need for cooperating genetic
alterations. Similarly, the option for an inducible conditional knockout may reduce compensatory
effects against Kat2a loss. Specifically, we crossed Kat2aFl/Fl C57Bl/6 mice (Lin et al., 2008) on the
interferon response-inducible Mx1-Cre+/- background, and generated a stable mouse line homozy-
gous for the Flox allele. Mx1-Cre-positive (KO) and Mx1-Cre-negative (WT) mice were compared
across all experiments (Figure 1—figure supplement 1A), with locus excision obtained through
treatment of experimental and control mice with intra-peritoneal polyinosylic-polycytidylic (pIpC)
acid (Chan et al., 2011). Excision was tested 4–6 weeks after injection and consistently achieved val-
ues greater than 80% in stem and progenitor cell compartments (Figure 1—figure supplement 1B),
reflected in a profound loss of gene expression, including amongst myeloid-biased (LMPP) and com-
mitted (GMP) progenitors critical for AML initiation (Goardon et al., 2011; Figure 1—figure supple-
ment 1C). Locus excision generates an in-frame product joining the first two and the last exons and
is transcribed (Figure 1—figure supplement 1D) but does not code for acetyl-transferase activity or
other functional domains (Figure 1—figure supplement 1A). Kat2a was dispensable for normal
mouse hematopoiesis, with minimal transient effects on the number (Figure 1—figure supplement
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1E) and in vitro activity (Figure 1—figure supplement 1F) of KO hematopoietic stem cells (HSC).
These effects were not sustained through aging (Figure 1—figure supplement 1G), and, crucially,
did not affect HSC function in vivo, measured by long-term reconstitution of irradiated recipients
through transplantation (Figure 1—figure supplement 1H).
Kat2a loss impairs establishment of MLL-AF9 leukemia
Having verified that Kat2a deletion does not perturb normal hematopoiesis and thus preserves can-
didate progenitor cells-of-origin for leukemia transformation, we used a retroviral delivery system to
express the MLL-AF9 leukemia fusion in progenitor-enriched, lineage-depleted (Lin-) WT and KO BM
cells. Cells were transformed in vitro through serial re-plating in semi-solid medium-based colony-
forming assays, with similar efficiency for both genotypes (Figure 1A). Importantly, the level of locus
excision was mildly increased during transformation (Figure 1B), indicating that loss of Kat2a does
not impede the initial selection of leukemia-transformed clones. Continued re-plating revealed that
Kat2a KO affected the type of colonies produced, with a shift from compact or type I
(Johnson et al., 2003) colonies (Figure 1C–D) with Kit+ progenitor-like cells (Figure 1E and Fig-
ure 1—figure supplement 2A–B), to mixed, or type II (Johnson et al., 2003) colonies (Figure 1F),
with a characteristic halo (Figure 1G and Figure 1—figure supplement 2C) of more differentiated
cells and a corresponding reduction in Kit-positive cells, which have higher levels of the differentia-
tion marker Mac1/CD11b (Figure 1H and Figure 1—figure supplement 2D). Compatible with the
serial re-plating experiments, cell lines established from MLL-AF9-transformed cell lines of both
Kat2a WT and KO genotypes exhibited a relative gain in mixed colonies (Figure 1—figure supple-
ment 2E), with higher levels of Mac1 (Figure 1—figure supplement 2F). Taken together, the data
suggest that Kat2a loss is permissive to MLL-AF9-driven transformation, but alters the balance
between in vitro self-renewal and differentiation, favoring the latter. We tested these observations in
vivo by monitoring leukemia development in mice that received WT and KO Lin- BM cells transduced
for 2 days with retrovirus encoding the MLL-AF9 oncogenic fusion. Kat2a KO recipient animals had a
moderate advantage in survival (Figure 2A), suggesting a protracted development of leukemia. Leu-
kemias were nevertheless depleted of Kat2a expression (Figure 2B), thus excluding selection of
escapee cells. WT and KO leukemic animals had similar disease burdens at the point of culling, as
measured by organ infiltration (Figure 2—figure supplement 1A) and peripheral blood counts (Fig-
ure 2—figure supplement 1B). In contrast with in vitro transformation, we did not observe gross
changes to the balance between progenitor and differentiated cells in the resulting WT vs KO leuke-
mias, which had preservation of phenotypic leukemia stem-like cells (LSC), defined by the Lin-Kit
+Sca1-CD34+CD16/32+ GMP surface phenotype (L-GMP) (Figure 2C). We reckoned that loss of
Kat2a affected the probability of leukemia development through dysregulation of transformed cells,
and sought to probe this hypothesis by investigating the transcriptional programs of WT and KO leu-
kemias at the single-cell level.
Kat2a KO leukemias have increased transcriptional variability
To this end, we pooled samples from 4 to 5 primary leukemias of each genotype, sorted live GFP+
cells reporting the presence of the MLL-AF9 fusion, and successfully sequenced over 4000 cells
Kat2a WT and KO cells each, for a total of 13166 transcripts, using a high-throughput 10X Genomics
platform (Zheng et al., 2017). Basic measures of gene alignment and quality control are summarized
in Supplementary file 1. In order to minimize the confounding effect of rarely or very low expression
genes, we filtered out transcripts detected in less than 10% of all cells, and only included cells where
a minimum of 500 different transcripts were detected. These filtering criteria match those recently
used in analysis of heterogeneity of hematological malignancies using a similar 10X Genomics plat-
form (Pastore et al., 2019) and were deliberately chosen for reproducibility. We thus focused the
analysis on what we designated Robust gene set. These were a total of 2588 genes
(Supplementary file 2), sampled from 7360 cells (3835 WT, 3525 KO), which captured general meta-
bolic, biosynthetic and regulatory ontologies, as well as hematopoietic-specific categories,
for example ‘myeloid cell differentiation’, indicating broad representation of transcriptional pro-
grams within the dataset (Supplementary file 3). We assessed gene expression using the D3E algo-
rithm (Delmans and Hemberg, 2016), which makes implicit use of the single-cell nature of the data
to extract information about differential dynamics of transcription, in addition to determining
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Figure 1. Conditional knockout of Kat2a promotes differentiation of MLL-AF9-transformed cells in vitro. (A) Serial re-plating of colony-forming cell
(CFC) assays of MLL-AF9 transformed cells, mean ± SEM, n = 3. (B) Excision efficiency was evaluated by qPCR during re-plating of MLL-AF9
transformed cells, mean ± SEM, n = 2–3, *p<0.01 and **p<0.001. (C) Proportion of Compact-type colonies in MLL-AF9 transformed cells on Kat2a WT
or KO background, mean ± SEM, n = 3, *p<0.01 and **p<0.001. (D) Representative photograph of a Compact-type colony. (E) Flow cytometry analysis
of the colony in (D). (F) Proportion of Mixed-type colonies in MLL-AF9 transformed cells on Kat2a WT or KO background, mean ± SEM, n = 3, *p<0.01
and **p<0.001. (G) Representative photograph of a Mixed-type colony. (H) Flow cytometry analysis of the colony in (G). Two-tailed t-test was performed
in (A), (B), (C) and (F).
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Figure 1 continued on next page
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changes in average gene expression. The algorithm views single-cell measurements as multiple
observations of the same or closely-related cells and fits a two-state promoter model that interprets
gene expression measurements in terms of frequency and size of bursts of promoter activity (Fig-
ure 3—figure supplement 1A). We used a multiple linear regression model to verify the contribu-
tion of burst size and frequency to average gene expression and gene expression CV in our single-
cell RNA-seq data (Figure 3—figure supplement 1B). In line with other studies (Hornung et al.,
2012), we observed that both bursting parameters contributed to mean expression to similar
extents, but there was a greater contribution of burst frequency to CV. Differential gene expression
analysis between Kat2a WT and KO primary leukemic cells revealed mild albeit significant changes in
average gene expression (Figure 3A; median difference  0.03), which were of down-regulation
upon Kat2a excision, as might be anticipated from loss of a histone acetyl-transferase. Compatible
with the proposed role of Kat2a in regulating transcriptional noise, we observed a significant
increase in gene expression variability as measured by coefficient of variation (CV = standard devia-
tion/mean) (Figure 3B; median difference 0.24) in Kat2a KO cells which was apparent at all levels of
gene expression (Figure 3C). The increase in gene expression CV associates with greater cell-to-cell
dispersion (Mohammed et al., 2017), in other words reduced cell-to-cell correlation in transcript lev-
els, amongst Kat2a KO leukemia cells (Figure 3D). The increased dispersion of transcriptional vari-
ability can be attributable to a change in burst frequency (Figure 3E; median difference  1.15), but
not burst size (Figure 3F). This has also been observed for the Kat2a yeast orthologue Gcn5 in mod-
ulating transcriptional noise (Weinberger et al., 2012).
Increased transcriptional variability associates with loss of Kat2a KO
leukemia stem-like cells
There have been several reports (Mohammed et al., 2017; Antolovic´ et al., 2017; Blake et al.,
2006; Chambers et al., 2007; Chang et al., 2008; Reynolds et al., 2012), including our own
(Pina et al., 2012), that suggest an association between variability in gene expression and probabil-
ity of cell fate change, although most of the data remains correlative, at least in mammalian systems.
Our recent analysis of Kat2a inhibition in mouse ES cells (Moris et al., 2018) is compatible with this
view, suggesting that the observed enhanced transcriptional variability may promote exit from pluri-
potency through disruption of gene regulatory networks. In this light, we asked if its enhancement in
Kat2a KO leukemias resulted in an imbalance of self-renewal vs differentiation states that could lead
to the observed delay in leukemia progression (Figure 2A). We made use of the RACE-ID algorithm
(Gru¨n et al., 2016) to cluster the combined 7360 WT and KO cells filtered as displaying Robust
gene expression, and optimally separated them into 12 clusters on the basis of the 500 most highly
variable genes in each genotype (Figure 4A). Despite the occupancy of a broadly similar transcrip-
tional space, the genotypes had differential cluster-association patterns, with some clusters, namely
7, 11 and 12, which together comprise 22.9% of WT cells, being relatively underrepresented
amongst Kat2a KO cells (respectively 0.5, 0.2 and 0.5 of Kat2a WT) (Figure 4—figure supplement
1A). Other clusters were over-represented amongst Kat2a KO cells but to a lesser extent, with only
2 over 1.5-fold (cluster 4–1.7-fold, 3.3% of WT cells; cluster 6–1.5-fold, 8.5% of WT cells), causing us
to focus on the Kat2a KO-depleted clusters. Unsupervised alignment of the 12 clusters along a puta-
tive differentiation trajectory, shows that the underrepresented clusters lie at its undifferentiated
end (Figure 4B). This is enriched for gene expression signatures associated with MLL self-renewal
(Figure 4—figure supplement 1B), suggesting a depletion of cells with stem-like characteristics.
Overall, gene expression programs at the start of the trajectory were similar between clusters 2, 4
and 7, with few genes unique to individual clusters thus preventing exploration of gene ontologies.
There were nevertheless subtle differences in the functional categories enriched amongst differen-
tially expressed genes between genotypes in each of the clusters, namely an association of
Figure 1 continued
Figure supplement 1. Loss of Kat2a does not affect normal hematopoiesis.
Figure supplement 1—source data 1. Colony-forming assays of Kat2a WT and KO stem and progenitor cells.
Figure supplement 2. Loss of Kat2a promotes differentiation of MLL-AF9 leukemia cells in vitro.
Figure supplement 2—source data 1. Differential colony counts from liquid cultures of MLL-AF9 transformed Kat2a WT and KO cells.
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categories associated with apoptosis in clusters 2
and 4, which were absent from cluster 7
(Supplementary file 4). The STEM-ID algorithm
builds on RACE-ID to define a ‘stemness’ score
that has successfully identified previously elusive
stem cell populations in mouse pancreas
(Gru¨n et al., 2016) and cellular hierarchies in
human liver (Aizarani et al., 2019). It postulates
that stem cells exhibit a multitude of incipient
lineage-affiliated programs (high information
entropy), which are shared (high connectivity)
with more differentiated cells, and attributes a
‘stemness’ score to each cluster as the product of
entropy and number of links (Figure 4—figure
supplement 1C). Indeed, cluster seven scores as
the most stem-like transcriptional state, suggest-
ing that Kat2a KO leukemias may be depleted of
functional, if not surface phenotype (Figure 2C),
LSC. We tested this by pooling equal numbers of
cells from all primary WT or all primary KO leuke-
mias in Figure 2A, and transplanting them into
secondary recipients at limiting cell doses.
Despite the equivalent number of phenotypic
LSC in the primary leukemias of both genotypes
(Figure 2C), recipients of Kat2a KO leukemia cells
failed to develop leukemia at the lowest cell
doses and had a dramatically reduced frequency
of functional LSC (Figure 4C–D), indicating that a
requirement for Kat2a in leukemia self-renewal
and/or propagation. Significantly, the level of
Kat2a gene expression knockout was profound
and retained in secondary leukemias, similar to
the primary leukemias they originated from (Fig-
ure 4—figure supplement 1D). In agreement,
the frequency of Kat2a KO cells escaping the
excision was negligible amongst phenotypically
undifferentiated Lin-Kit+Sca1-CD16/32+ cells
(Figure 4—figure supplement 1E). This confir-
mation of a maintained and profound gene
expression knockout with minimum contribution
from undeleted cells is particularly important, as
the persistence of a rearranged transcript fusing
exons 1, 2 and 18 (Figure 1—figure supplement
1D) prevents knockout quantification in the 3’-
biased 10X Genomics platform. In contrast, the
Taqman assay and the nested primers in the PCR
analyses (Figure 4—figure supplement 1D–E)
are directed at exons 6–7 and 11–13, respec-
tively, which capture the excised region. Thus,
cellular and molecular analyses, including inspec-
tion of transcriptional variability, are likely mini-
mally affected by the presence of cells escaping
Kat2a gene deletion, and should truly reflect the
effects of Kat2a loss. Secondary leukemias, like
primary leukemias, did not have a reduction in
surface phenotypic LSC (L-GMP, Figure 4E),
B
p=0.05
A
C
Figure 2. Kat2a loss impairs establishment of MLL-AF9
leukemia in vivo. (A) Survival curve of animals
transplanted with MLL-AF9 transformed Kat2a WT or
KO cells. N = 5 animals/genotype; log rank test,
p=0.05. (B) Relative expression (quantitative RT-PCR) of
Kat2a in MLL-AF9 primary leukemia BM cells from
Kat2a WT and KO backgrounds, mean ± SEM, n = 3,
**p<0.001, 2-tailed t-test. (C) Flow cytometry analysis of
BM cellularity of primary Kat2a WT or KO leukemias:
shown are late (Mac1+Gr1+) and early (Mac1+Gr1-)
differentiated populations and
Gr1-Mac1-cKit+Sca1-CD34+FcgR+ candidate stem-like
L-GMP cells, mean ± SEM, n = 4–5; 2-tailed t-test
performed.
The online version of this article includes the following
figure supplement(s) for figure 2:
Figure supplement 1. Primary Kat2a WT and KO MLL-
AF9 leukemias have similar disease burden.
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Figure 3. Loss of Kat2a increases transcriptional heterogeneity of primary MLL-AF9 leukemias. (A) Mean gene expression levels in Kat2a WT and KO
primary leukemia cells. Median and 95% CI of mean gene expression levels for the 2588 genes in the Robust gene set, across 7360 cells Kolmogorov-
Smirnov (KS) non-parametric test, p-value<0.01. (B) Gene expression CV in Kat2a WT and KO primary leukemia cells. Data as in (A) : KS non-parametric
test, p-value<0.01. (C) Binned gene expression CV across the distribution of gene expression averages for Kat2a WT and KO primary leukemia cells, KS
non-parametric test, p-value<0.05 for all bins. (D) Pair-wise distance measure between any two genes across Kat2a-WT and KO primary leukemia cells.
The top 500 most variable genes in the Robust gene set for each genotype, as determined by distance to the mean CV, were used, as previously
Figure 3 continued on next page
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putatively highlighting a dissociation between primitive surface phenotype and function, or
highlighting the existence of multiple stem-like states, as suggested by cluster-specific depletion at
the undifferentiated end of the Kat2a KO leukemia trajectory. Nevertheless, secondary leukemias
displayed an increased proportion of early (Mac1+Gr1-), but not late (Mac1+Gr1+) differentiated
myelo-monocytic cells (Figure 4E), suggesting that loss of Kat2a may perturb self-renewal and differ-
entiation progression at multiple levels. Accordingly, we observed reduction of transcriptional burst
frequency in KO cells to be prevalent across clusters, albeit slightly more marked at the undifferenti-
ated end (Figure 4—figure supplement 1F). The exception are the central clusters 11 and 12, which
have minimal representation in Kat2a KO leukemia (Figure 4—figure supplement 1A). Also, sepa-
rate inspection of the differentiation trajectories for Kat2a WT (Figure 4—figure supplement 2A–B)
and Kat2a KO cells (Figure 4—figure supplement 2C–D) suggests that the almost linear develop-
mental relationship between WT leukemia cells is replaced by multiple branching decisions upon
Kat2a loss, an observation also captured by a second pseudo-time trajectory algorithm (Figure 4—
figure supplement 2E–F). In summary, loss of Kat2a depletes functional LSC and alters cellular hier-
archies within MLL-AF9 leukemia. This is likely achieved through perturbation of promoter activity
and we sought to define the genes and pathways directly regulated by Kat2a.
Kat2a regulates transcription factor binding and bursting activity of
promoters
We defined Kat2a regulatory targets by chromatin immunoprecipitation followed by next genera-
tion-sequencing (ChIP-seq). Kat2a is a histone acetyl-transferase required for deposition of the activ-
ating H3K9 acetylation (ac) mark (Jin et al., 2014) and capable of catalyzing multiple acetyl-
modifications (Kuo and Andrews, 2013) at promoters and at enhancers (Krebs et al., 2011). We
identified promoters as H3K4 tri-methyl (me3) peaks (Figure 5—figure supplement 1A) and
enhancers with H3K4 mono-methyl (me1)- enriched regions (Figure 5—figure supplement 1B) and
inspected the respective pattern of distribution of H3K9ac in pooled MLL-AF9 primary leukemias ini-
tiated by Kat2a KO or WT cells. Experiments were performed in duplicate, with good overlap
between replicates (Figure 5—figure supplement 1C–D). We included analysis of another acetyla-
tion activation mark, H3K27ac, which associates with active enhancers (Creyghton et al., 2010), but
has not been specifically linked to Kat2a activity. Inspection of peak overlaps between methylation
and acetylation marks indicated a specific depletion of H3K9ac binding at promoters in regions
devoid of concomitant H3K27ac activation mark (Figure 5A). Conversely, H3K9ac was mildly
increased at candidate active enhancer regions marked by the presence of H3K27ac (Figure 5—fig-
ure supplement 1E) suggesting a possible pattern of imbalance of H3K9ac regulation between pro-
moters and enhancers. Guided by these preliminary observations, we focused on those promoter
peaks with unique loss of H3K9ac upon Kat2a depletion, and used the ENCODE database
(Auerbach et al., 2013) to confirm enriched experimental binding of Kat2a (aka GCN5) in other
model systems (Figure 5B and Supplementary file 5). Genes associated with differentially-acety-
lated promoter peaks represented general nucleic acid and mitochondrial metabolic categories
(Supplementary file 6). Somewhat surprisingly, the list of target promoters failed to include most
MLL-AF9 ChIP targets (Bernt et al., 2011) with the leukemia self-renewal associated Hox gene sig-
nature, namely Hoxa9, Hoxa10 and Meis1, escaping Kat2a-dependent promoter acetylation control.
This suggests that Kat2a-mediated maintenance of LSC may be achieved through general, rather
Figure 3 continued
described (Mohammed et al., 2017). Welch t-test for comparison of means *p-value<0.01. (E) Distribution of burst frequencies for the Robust gene set
in Kat2a WT and KO primary leukemias, as calculated by the D3E algorithm. KS non-parametric test, * p-value<0.0001. (F) Distribution of burst sizes for
the Robust gene set in Kat2a WT and KO primary leukemias, as calculated by the D3E algorithm. KS non-parametric test, non-significant.
The online version of this article includes the following source data, source code and figure supplement(s) for figure 3:
Source code 1. Binned CV analysis - R-language code and input matrix, source code for Figure 3C.
Source code 2. Pairwise distance measure - R-language code, source code for Figure 3D.
Source data 1. D3E output analysis of the Robust gene set with annotation of Kat2a acetylation targets.
Figure supplement 1. Differential transcriptional heterogeneity in Kat2a WT and KO MLL-AF9 primary leukemias.
Figure supplement 1—source code 1. Multiple linear regression analysis - R-language code and input data, source code for Figure 3—figure supple-
ment 1.
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Figure 4. Kat2a loss depletes functional MLL-AF9 leukemia stem-like cells. (A) t-SNE plot of single-cell RNA-seq data for Kat2a WT (left) and KO (right)
primary leukemic cells. RACE-ID K-means clustering was used to classify cells from Kat2a WT and KO primary leukemias in combination, on the basis of
the expression of the most highly variable genes from each genotype as defined in Figure 2D. Clusters are color-coded and cells of each genotype
were displayed separately for easier appreciation of their non-overlapping transcriptional spaces. (B) STEM-ID trajectory plot of analysis in (A)
representing combined measures of information entropy and cluster connectivity strength; clusters as in (A). (C) Extreme Limiting Dilution Analysis
(ELDA Hu and Smyth, 2009) of leukemia-initiating cell frequency in Kat2a WT and KO primary leukemias. Primary leukemias of each genotype were
pooled (WT-5; KO-4) and transplanted as 50K, 5K and 500 cell doses into 3–4 animals/dose group. (D) Survival curve of secondary recipients of MLL-
AF9 leukemic cells from Kat2a WT and KO backgrounds; data as in (C). Log rank test for difference in survival, n = 3–4/per dose group. 50 K cells
p=0.26, 5 K cells p=0.1, 500 cells p=0.02. (E) Flow cytometry analysis of BM cells from secondary Kat2a WT and KO leukemia transplant recipients (50K
and 5 K cells). Cell compartments as in Figure 2C; n = 6; mean ± SEM, 2-tailed t-test, **p<0.001, *p<0.01, and L-GMPs p=0.07.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source code 1. tSNE plot of single-cell RNA-seq data - R-language code and individual cell coordinates with respective cluster ID, source code for
Figure 4A.
Figure supplement 1. Kat2a WT and KO MLL-AF9 primary leukemias have distinct cluster composition and organization.
Figure supplement 2. Kat2a WT and KO MLL-AF9 primary leukemias have unique differentiation trajectories.
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Figure 5. Loss of Kat2a depletes H3K9ac and perturbs transcription factor-binding in a subset of regulatory gene promoters. (A) Quantification of
H3K9ac and H3K27ac ChIPseq peaks at H3K4me3 gene promoters in Kat2a WT and KO primary MLL-AF9 leukemias. (B) Top ENCODE ChIP-seq
Significance Tool enrichments for H3K9ac-positive promoters exclusive to Kat2a WT primary MLL-AF9 leukemia cells. These promoters constitute Kat2a
acetylation targets. (C) Distribution of burst frequencies for Kat2a acetylation targets vs. non-targets within the 2588-Robust gene set. Values as
Figure 5 continued on next page
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than leukemia-specific, regulatory programs, with putative implications for other leukemic and non-
leukemic malignancies. Having previously observed that loss of Kat2a associates with a decrease in
frequency of transcriptional bursting (Figure 3E), we asked if this was more evident for genes
dependent on Kat2a for promoter H3K9ac. Global inspection of the Robust gene set across all cells
showed a similar reduction in burst frequency for Kat2a acetylation targets and non-targets
(Figure 5C). However, H3K9ac target genes had uniquely preserved mean gene expression levels
(95% CI KO-WT means =  0.1118 to 0.01303, Welch t-test p=0.12 for targets vs.  0.0894 to
 0.0016, p=0.04 for non-targets), with increased CV upon Kat2a KO (both groups p<0.0001), sug-
gesting a specific impact of Kat2a on variability of transcription. Nevertheless, global analysis of tran-
scriptional burst frequency failed to produce a specific association with Kat2a acetylation targets,
which could be due to a confounding effect of mixing cells at different points in the differentiation
trajectory, for which locus-specific regulation might differ, or indeed a cascading of transcriptional
consequences along gene regulatory networks, as suggested by our analysis of mouse ES cells
where Kat2a activity was inhibited (Moris et al., 2018). Alternatively, the lack of association could
reflect the fact that our subset of acetylation targets captures absolute, but not relative losses of
promoter H3K9ac upon Kat2a KO, as a result of the necessarily limited replication of ChIP analysis of
primary leukemia cells. To avoid potential confounding effects of cellular heterogeneity on determi-
nation of transcriptional parameters, we repeated the analysis exclusively on stem-like cluster 7 cells.
Indeed, by using a more homogeneous group of cells, we could observe that the reduction in fre-
quency of bursting in Kat2a KO cells was significantly more marked for H3K9ac target genes
(Figure 5D; Mann-Whitney test for difference in burst frequency, Fburst, defined as (FburstKO-
FBurstWT)/FburstWT p=0.0155), indeed suggesting that Kat2a acts by regulating bursting activity at
target promoters. Transcriptional variability has been associated with density of transcription factor
binding. As Kat2a is known to interact with transcription factors, including the oncogene Myc
(Wang et al., 2018; Hirsch et al., 2015), to regulate common downstream gene expression pro-
grams, we asked if loss of Kat2a reduced transcription factor binding at target H3K9ac peaks. Analy-
sis of H3K9ac targets using the ENCODE ChIP-Seq significance tool suggested binding by Myc in
other experimental systems (Supplementary file 3), in addition to general transcription and pause-
release factors. It also showed increased binding by the respiratory chain regulator Gabpa
(Ongwijitwat and Wong-Riley, 2005) (Nrf2 in the ENCODE database), which has been described as
a regulator of normal hematopoietic and Chronic Myeloid Leukemia (CML) stem cells
(Manukjan et al., 2016; Yang et al., 2013). We performed ChIP-qPCR analysis of Myc and Gabpa
binding at promoter peaks depleted of H3K9ac binding in Kat2a KO leukemias. We selected candi-
date Myc and Gabpa target peaks based on experimental DNA occupancy by the transcription fac-
tors (TF) across different mouse cell types in the ENCODE database. Q-PCR primers were designed
under the respective H3K9ac peak, for analysis of pooled mouse MLL-AF9 secondary leukemia sam-
ples of each genotype. We confirmed that the transcription factors (TF) Myc and Gabpa did indeed
bind at most of the locations analyzed in MLL-AF9 leukemias (Figure 5E–F and Figure 5—figure
supplement 2A–B). Critically, we observed that binding of both TF at promoter regions dependent
on Kat2a for H3K9ac was globally reduced in Kat2a KO leukemias (Figure 5E–F) as compared to WT
Figure 5 continued
calculated by D3E with 2585 genes called differential. Mann-Whitney non-parametric test for comparison of rank medians; p<0.0001 for Kat2a WT vs.
KO comparisons. WT vs KO median rank differential non-significant. (D) Distribution of burst frequencies for Kat2a acetylation targets vs. non-targets
amongst cells in cluster 7; 857 genes considered as used in RACE-ID. Burst frequencies were calculated by D3E, with 332 genes called differential.
Mann-Whitney non-parametric test for comparison of rank medians; p<0.001 for Kat2a WT vs. KO comparisons. (E) ChIP-quantitative PCR analysis of
Myc binding in selected Kat2a acetylation target promoter peaks; mean values for 2–4 independent experiments using pooled BM or Spleen of Kat2a
WT vs KO MLL-AF9 secondary leukemias. Mean enrichments: WT = 2.158, KO = 1.357, 95% CI of difference 0.01273 to 1.589; 2-way ANOVA p<0.05 for
genotype contribution. (F) ChIP-quantitative PCR analysis of Gabpa binding in selected Kat2a acetylation target promoter peaks; mean values for two
independent experiments using pooled BM of Kat2a WT vs KO MLL-AF9 secondary leukemias. Mean enrichments: WT = 1.775, KO = 0.9609, 95% CI of
difference 0.2640 to 1.364; 2-way ANOVA p<0.01 for genotype contribution.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. D3E output analysis of cluster seven with annotation of Kat2a acetylation targets.
Figure supplement 1. ChIP identification of regulatory regions in primary MLL-AF9 leukemia.
Figure supplement 2. Loss of Kat2a affects transcription factor binding in a subset of loci.
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(Myc: 95% CI WT-KO enrichment 0.01273 to 1.589; 2-way ANOVA p<0.05 for genotype contribu-
tion; Gabpa: 95% CI WT-KO enrichment 0.2640 to 1.364; 2-way ANOVA p<0.01 for genotype contri-
bution), thus suggesting that Kat2a may regulate binding of sequence-specific TF at the promoter
regions it acetylates.
Kat2a participates in AML maintenance through regulation of
translation-associated genes
Having established that Kat2a can control the H3K9ac status, and putatively TF binding, of a subset
of promoters, with impact on their bursting activity, we focused on the nature of the genes showing
reduced frequency of bursting in Kat2a KO leukemias. We found that these were preferentially asso-
ciated with translation categories (Supplementary file 7), including ribosomal proteins and transla-
tion initiation and elongation factors, some of which we showed to be depleted of TF binding upon
Kat2a loss. Additionally, we could observe an enrichment of translation-associated gene expression
signatures amongst undifferentiated cells relatively depleted in Kat2a KO leukemias (Figure 6A),
suggesting that they may contribute to leukemia propagation and/or maintenance. We started by
verifying that perturbed regulation by Kat2a had functional consequences for the translation machin-
ery by performing polysomal profiling of MLL-AF9-carrying MOLM-13 AML cells in which KAT2A
activity was inhibited by the MB-3 inhibitor (Tzelepis et al., 2016). Reassuringly, we observed a dra-
matic reduction in polysomal content (Figure 6B), indicating the functional impact of Kat2a transcrip-
tional control, despite minimum changes in average gene expression. We then tested the effect on
emergent protein synthesis in mouse MLL-AF9 leukemias by quantifying OP-Puro incorporation in
Kat2a WT and KO phenotypic L-GMP. We saw qualitative and quantitative reductions in OP-Puro
incorporation in Kat2a KO cells, with a bimodal distribution of low and high incorporating cells that
was unique to Kat2a-depleted cells (Figure 6C), and significantly lower levels protein synthesis within
the high OP-Puro distribution (Figure 6D). Altogether, the data suggest that phenotypic leukemia
stem-like cells are less translationally active in the absence of Kat2a, which could explain their
reduced functionality. We assessed functional impact in vitro by inhibiting the translation machinery
of Kat2a WT and KO MLL-AF9 transformed cells with the S6K1 inhibitor PF4708671 (Pearce et al.,
2010). PF4708671 targets the TOR pathway and impedes translation initiation and elongation.
Treatment of MLL-AF9 transformed primary mouse BM cultured cells with PF4708671 in colony-
forming assays recaptured the imbalance between compact and mixed colonies (Figure 6E)
observed upon in vitro transformation of Kat2a KO cells. Taken together, the data indicate that reg-
ulation of the translational machinery at least partially mediates the imbalance between self-renewal
and differentiation observed in MLL-AF9-driven leukemia upon Kat2a loss. It further supports the
notion that fine control of transcriptional activity leading to changes in variability of transcript levels
influences cell fate transitions and can be exploited by malignant cells for cancer maintenance.
Discussion
In this study, we combine functional assays with single-cell transcriptional analysis and identify a
requirement for the histone acetyl-transferase Kat2a in sustaining leukemia stem-like cells (LSC) and
their downstream leukemia cellular structure in MLL-AF9-initiated AML. Loss of Kat2a increases cell-
to-cell variability in transcription at all levels of mean gene expression, which is reflected in poor
coordination in gene expression programs in Kat2a KO leukemia cells. Perturbation of transcription
associates with an increased trend towards differentiation in vitro and loss of long-term functional
LSC in vivo. However, the differentiation routes followed by Kat2a KO leukemic cells are aberrant
and seem to follow multiple alternative dead ends that deviate from the seemingly linear pathway of
Kat2a WT MLL-AF9 cells. These characteristics are reminiscent of the perturbation of pluripotency
we observed in Kat2a-inhibited mouse embryonic stem (mES) cells (Moris et al., 2018), where cells
accumulate at the exit from pluripotency and only progress to differentiation with slow kinetics.
Indeed, that may be the expected outcome of constitutively enhancing variability in gene expres-
sion, or transcriptional noise, which may need to be buffered downstream of a differentiation transi-
tion for differentiation to proceed (Ahrends et al., 2014).
Although it is surprising that we do not observe changes to normal hematopoietic stem and pro-
genitor cells, the same was reported by others using a tissue-specific developmental (Vav-Cre)
knockout (Bararia et al., 2016). Stem cell and developmental systems are typically robust to noise
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Figure 6. Kat2a regulates protein synthesis activity in MLL-AF9 leukemia stem-like cells. (A) Expression of translation-associated gene signatures in
individual cells along the global MLL-AF9 STEM-ID pseudotime trajectory. Trajectory representation as in Figure 4A, with both genotypes in the same
plot. Gene signature defined as per the representation of gene sets MORF_EIF4E, MORF_EIF3S2, MORF_EIF4A2, MORF_EIF3S6 (MSigDB) in the
Robust geneset. (B) Polysomal profiling of MOLM-13 cells upon overnight treatment with DMSO or the Kat2a inhibitor MB-3 (Biel et al., 2004) (200
mM); data are representative of 2 independent experiments. (C) Flow cytometry plot of OP-Puro incorporation by phenotypic L-GMP isolated from
spleens of MLL-AF9 secondary leukemias WT or KO for the Kat2a gene. This pattern was observed in 2 out of 3 Kat2a KO leukemias analysed (0/3 WT).
(D) Quantitation of protein synthesis rate in Kat2a WT and KO L-GMP as measured by OP-Puro incorporation. Mean ± SEM; n = 3 individual leukemia
Figure 6 continued on next page
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perturbations (Urban and Johnston, 2018), and may have compensatory systems that buffer the
loss of Kat2a. A putative compensatory mechanism would be the up-regulation of the Kat2a ortho-
logue Pcaf/Kat2b, which is normally absent in HSC and progenitors. Whilst we did not observe up-
regulation of Kat2b in leukemia cells, we did not specifically look for it in normal hematopoiesis, and
cannot exclude that it may explain the difference between healthy and leukemic blood cells. We did
note a very early reduction in HSC and their multilineage colony-forming potential upon Kat2a loss,
but this was not sustained and did not affect engraftment potential, a more accurate measure of
HSC activity. Also, the Kat2a KO hematopoietic system did not exhibit increased sensitivity to pro-
longed treatment with the cytotoxic drug 5-fluorouracil (data not shown), suggesting that KO and
WT HSC are similarly functional. Although we cannot exclude that serial or competitive transplanta-
tion may reveal a defect in Kat2a KO HSC, our data are nevertheless supportive of a difference in
the sensitivity of leukemia cells to Kat2a loss.
It has been proposed that cancer cells exist in a state of enhanced transcriptional activity that is
required to sustain their oncogenic self-renewal programs (Lin et al., 2012). Amongst other factors,
hyper-transcription has been associated with Myc, a known collaborator of Kat2a in transcriptional
regulation (Hirsch et al., 2015), which is broadly required in AML (Delgado and Leo´n, 2010), includ-
ing in MLL fusion-driven disease (Schreiner et al., 2001). Accordingly, we found Myc to be depleted
in a subset of promoters targeted by Kat2a. However, transcription factor depletion at promoters
was not exclusive to Myc, and we made similar and indeed more extensive observations with
another broad metabolic regulator, Gabpa, which has been previously characterized as a regulator
of CML self-renewal (Yang et al., 2013; Yu et al., 2012) and associated with Kat2a-containing com-
plexes (Krebs et al., 2011), but for which a requirement in AML has not been established. Of inter-
est, loss of both transcription factors analysed have severe consequences to normal hematopoiesis,
which are of HSC depletion in the case of Gabpa (Manukjan et al., 2016; Yu et al., 2011) and
impaired differentiation with accumulation of defective phenotypic HSC in the case of Myc
(Wilson et al., 2004). Notably, none of these roles is phenocopied by Kat2a loss. We thus suggest
that Kat2a acts through co-option of the transcriptional machinery present at target loci, rather than
rely on a unique conserved transcription factor circuit, to exert its pleiotropic activating effects in
leukemia cells. This said, we did not observe a monotonous reduction in transcription factor binding
across all loci analysed, suggesting that the presence of Kat2a may facilitate transcription factor
recruitment and/or binding in a probabilistic manner, a view compatible with a role for Kat2a in sta-
bilizing rather than initiating transcription (Jin et al., 2014). Live-cell imaging of transcription factor
recruitment to individual loci (Donovan et al., 2019) and/or single-cell ChIP (Ai et al., 2019;
Hainer et al., 2019; Ku et al., 2019), currently undergoing significant development, will be central
to definitively test this hypothesis. An alternative, albeit not mutually exclusive, explanation is that
the role of Kat2a in transcription factor binding or recruitment is influenced by the chromatin context
in which it acts, including the post-translational modifications it catalyses as well as the modifications
introduced by other factors.
Kat2a catalyzes acetylation of Lys nine in Histone 3 (H3K9ac), a chromatin mark associated with
maintenance, but not initiation, of locus transcription. Kat2a is able to catalyze acetylation of addi-
tional lysine residues in cell-free systems (Kuo and Andrews, 2013), but its loss in vivo more specifi-
cally affects H3K9ac, particularly so in the vicinity of transcriptional start sites (Wang et al., 2018).
Compatible with these observations, Kat2a loss in the context of MLL-AF9 leukemia impacted
H3K9ac specifically at gene promoters. In addition, H3K9ac was specifically lost at gene loci that do
not exhibit additional activating acetylation marks such as H3K27ac. Whilst the specific meaning of
single vs. double-acetylated regions is unclear, one possibility is that the presence of H3K27ac marks
genomic regions that also function as enhancers of more distant genes, suggesting that Kat2a may
be strictly required at promoters. In agreement with this view, we did not observe loss of H3K9ac at
Figure 6 continued
samples/genotype; *p<0.001. (E) Proportion of colonies types in CFC assays of Kat2a WT cells treated with DMSO vs. S6K1 PF4708671 inhibitor, mean
+ SEM, n = 3, ***p<0.001, *p<0.05. 2-tailed paired t-test performed in (D) and (E).
The online version of this article includes the following source data for figure 6:
Source data 1. Differential colony counts of MLL-AF9-transformed cells treated with PF4708671 S6K1 inhibitor.
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H3K4me1-positive enhancers. Instead, we observed a gain in H3K27ac at both H3K4me3 promoters
and H3K4me1 enhancers as a single acetylation mark, which may help explain the minimal conse-
quences of Kat2a loss in terms of average gene expression, and highlight the specific role of Kat2a-
dependent H3K9ac of promoters in stabilizing transcriptional activity. Gain of H3K27ac may reflect
differentially regulated or compensatory acetylation by other histone acetyl-transferases in the
absence of Kat2a. In light of the promoter vs. enhancer specificity of the changes observed, it will be
interesting to investigate to what extent reprogramming of acetylation marks reflects proximal
reconfiguration of enhancer-promoter interaction via Ctcf binding. Ctcf loss has been shown to
increase gene expression CV with moderate or no differences in mean expression (Ren et al., 2017),
a pattern akin to our observations upon Kat2a loss. Whereas their study specifically investigated
sequence-driven loss of Ctcf binding at proximal, intra-TAD enhancer regions, we observed that
H3K9ac-depleted promoters in Kat2a KO leukemia cells had a significant association with experi-
mental Ctcf binding in ENCODE experiments, and we speculate that Ctcf may be dislodged to
enhancers and promote asymmetric distribution of histone acetylation marks, with dysregulation of
locus control. Of note, too, is the fact that despite the almost complete knockout of Kat2a expres-
sion, the loss of H3K9ac, although specific in terms of chromatin context, is far from dramatic. This is
similar to recent observations in embryoid bodies (Wang et al., 2018) and suggests that Kat2a
requirement for H3K9ac is not absolute, although it may be locus-specific. Other acetyltransferases
may, either normally or compensatorily, contribute to H3K9 acetylation in at least some locations,
and it will be interesting to understand the parameters that determine specific dependency on
Kat2a activity and its unique consequences to transcription.
Variability in gene expression levels reflects regulation of locus activity, and whilst specific contri-
bution from enhancers has been proposed (Fukaya et al., 2016) and remains an area of active inves-
tigation (Larsson et al., 2019) the role of promoter configuration and sequence has been more
extensively characterized in multiple model systems (Antolovic´ et al., 2017; Faure et al., 2017;
Zoller et al., 2015). In most if not all loci, transcriptional activity is discontinuous, with promoters
cycling between active (ON) and inactive (OFF) states. Self-limited bursts of transcriptional activity
are characterized by the burst frequency, reflecting the rate of OFF-to-ON transitions, and the burst
size, which captures the number of mRNA molecules produced during each burst. In yeast, regula-
tion of both burst parameters is dependent on H3K9ac at specific gene locations: gene body acety-
lation regulates burst size; promoter H3K9ac associates primarily with burst frequency
(Weinberger et al., 2012). Furthermore, in yeast, promoter H3K9ac is deposited by the Kat2a ortho-
logue and founder histone acetyl-transferase Gcn5, and removed by the Sin3a orthologue Rpd3(L)
deacetylase complex. Loss of Gcn5 decreases burst frequency across multiple yeast loci and has
been modelled to increase intrinsic transcriptional noise, a finding we capture in mammalian cells in
the present study. Whilst our study specifically links promoter H3K9ac to regulation of burst fre-
quency in mammalian cells, recent work by the Nae¨f lab has shown that locus-specific manipulation
of promoter, but not distal or enhancer, H3K27ac can also change transcriptional bursting frequency
(Nicolas et al., 2018). Although the Nae¨f study has not specifically manipulated H3K9ac levels, it did
reveal an association between promoter H3K9ac and frequency of locus activation, which agrees
with our own observations. Whether other residue-specific acetylations of promoters (or indeed
enhancers) can produce the same effect remains to be determined, and this knowledge will
undoubtedly deepen current understanding of transcriptional regulation. Moreover, Kat2a was
recently shown to catalyze other acyl-modifications of lysine residues, namely succinylation
(Wang et al., 2017), which also associates with transcriptional activation (Tong et al., 2020). Charac-
terization of the exact mechanistic consequences of additional acylations and their interaction with
the better characterized lysine acetylations is still lacking, not least due to lack of modification and
residue-specific antibodies for the newly-identified marks. It is possible that their loss also contrib-
utes to the changes in transcriptional regulation seen upon Kat2a KO, and could for example explain
why the reduction in frequency of bursting, although more strongly associated with loss of H3K9ac,
is not exclusive to sites depleted of this modification. Additionally, it remains possible that loss of
Kat2a may impact other residue-specific acylations more dramatically than its specific effect on
H3K9ac and the effects of their combined loss more completely link all the effects observed. Our lab
has recently developed a KAT2A-dCas9 fusion capable of catalyzing targeted acetylation events
(data not shown), which will be instrumental in the mechanistic understanding of individual acetyla-
tion events and specific sequences in regulating bursting activity. It should also allow us to probe
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other candidate acyl modifications to unveil their unique and combined effects on transcriptional
bursting.
Somewhat unexpectedly, we found that the genes regulated by Kat2a at the level of promoter
acetylation, and which responded to Kat2a loss with decreased frequency of bursting, were specifi-
cally associated with ribosomal assembly and translation activity. Similar categories have been shown
to be regulated by non-catalytic components of the Kat2a SAGA complex in controlling ESC pluripo-
tency (Seruggia et al., 2019), reinforcing the notion that Kat2a complexes impact general metabolic
processes in multiple cell types, and that these general processes can specifically influence cell fate
transitions. Importantly, we demonstrated that Kat2a-depleted leukemia stem-like cells (phenotypic
L-GMP) have reduced protein synthesis activity, putatively due to a perturbation of polysomal
assembly consequent to variability in levels of ribosomal proteins. Moreover, perturbation of the
translational machinery could re-capture the enhanced in vitro differentiation of leukemia cells
observed upon Kat2a depletion, suggesting that alterations in protein synthesis activity may indeed
be central to exit from leukemia self-renewal. In agreement, Morrison and collaborators
(Signer et al., 2014) had previously reported that impaired protein synthesis upon genetic depletion
of the ribosomal protein machinery impedes leukemia self-renewal, whilst having non-linear dose-
dependent effects on normal hematopoiesis, mimicking our own observations in the Kat2a KO
setting.
Future studies directing Kat2a catalytic activity to single or multiple loci will illuminate individual
vs. global target gene contributions to the leukemia phenotype. However, it is tempting to speculate
that the generic nature of the programs impacted by Kat2a at the level of transcriptional noise may
configure an underlying propensity towards execution of cell fate transitions, which can be of a dif-
ferent nature in different biological contexts. Analysis of the impact of Kat2a target programs in
other malignant and normal stem cell systems, or at different stages of leukemia progression will
test this hypothesis. It will also be interesting to determine if other candidate regulators of transcrip-
tional noise produce similar effects and can be exploited therapeutically in AML, as well as in other
hematological and non-hematological malignancies.
Materials and methods
Generation and analysis of Kat2a conditional knockout mice
Kat2aFl/Fl conditional knockout mice (Lin et al., 2008) (MGI:3801321) were bred with Mx1-Cre +/-
transgenic mice (Ku¨hn et al., 1995), in a C57Bl/6 background. Littermates were genotyped for
Kat2a LoxP sites (forward: CACAGAGCTTCTTGGAGACC; reverse: GGCTTGATTCCTGTACCTCC)
and for Mx1-Cre: (forward: CGTACTGACGGTGGGAGAAT; reverse: TGCATGATCTCCGGTATTGA):
Ear notch biopsies were digested using KAPA express extract (Sigma Aldrich) and KAPA2G ROBUST
HS RM Master Mix (2x) (Sigma Aldrich). PCR cycling protocol: 95C, 3 min; 40x (95˚C, 15 s; 60˚C, 15
s; 72˚C, 60 s); 72˚C, 60 s. DNA products were run on a 1% Agarose Gel in TAE (1x), at 100V and visu-
alized using an AlphaImager UV transilluminator (Protein Simple). Cre-mediated recombination was
induced in 6–10 week-old mice by administration of 5 alternate-day intraperitoneal injections of poly
(I)- poly(C) (pIpC), 300 mg/dose. After pIpC treatment, animals were identified as Kat2a WT = Kat2
aFl/Fl * Mx1-Cre -/- and Kat2a KO = Kat2 aFl/Fl * Mx1-Cre +/-. Excision efficiency was determined by
qPCR of genomic DNA (gDNA) from Peripheral Blood (PB), Spleen (Sp) or Bone Marrow (BM).
gDNA was extracted using Blood and Tissue DNA easy Kit (Qiagen) and quantified by Nanodrop
(Thermo Scientific). qPCR analysis used Sybr Green Master Mix (Applied Biosystems) and two sets of
primers (Figure 1A): Kat2a-IN11 (forward: CAACTTCCCCAAGGTATGGA; reverse: CGGGGACC
TTAGACTTGTGA), within the excised region; Kat2a-OUT18 (forward: AGTCTGGGCTGTTTCCATGT;
reverse: GCCCGTTGTAGAATGTCTGG), distal to the second LoxP site. Expression levels were
determined by the Pfaffl method following normalization to Kat2a-OUT. PB was collected by saphe-
nous vein and differential blood cells counts were determined using a Vet abc automated counter
(Scil Animal Care, Viernheim, Germany). Mice were kept in an SPF animal facility, and all experimen-
tal work was carried out under UK Home Office regulations. Animal research was regulated under
the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review
by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB).
Domingues et al. eLife 2020;9:e51754. DOI: https://doi.org/10.7554/eLife.51754 17 of 29
Research article Cancer Biology Chromosomes and Gene Expression
Isolation of mouse BM stem and progenitor cells
BM was isolated from mouse long bones as described before (Pina et al., 2015). Following red
blood cell lysis, total BM suspension was depleted of differentiated cells using a cocktail of biotiny-
lated lineage (Lin) antibodies (Table 1) and streptavidin-labeled magnetic nanobeads (Biolegend),
according to manufacturers’ instructions. Cells were directly used in transplants, colony-forming
assays or flow cytometry for analysis of normal hematopoiesis. For leukemia studies, cells were cul-
tured overnight at 37˚C 5% CO2 in RPMI supplemented with 20% Hi-FBS (R20), 2 mg/mL L-Gluta-
mine, 1% PSA, 10 ng/mL of murine Interleukin 3 (mIL3), 10 ng/mL of murine Interleukin 6 (mIL6), and
20 ng/mL of murine Stem Cell Factor (mSCF) (cytokines from Peprotech) (supplemented R20), fol-
lowed by retroviral transduction.
Colony forming cell (CFC) assays
For analysis of normal progenitors, sorted mouse BM cells were plated at a density of 200–400 cells/
plate in duplicates, in MethoCult GF M3434 (STEMCELL Technologies). Colonies were scored at 7–9
days. For analysis of MLL-AF9 leukemia, retroviral-transduced BM cells were plated in M3434 at an
initial density of 10000 cells/condition and scored and re-plated every 6–7 days. Re-plating was per-
formed up to passage 9, with 4000 cells/condition used from plate 3. CFC assays from mouse MLL-
AF9 transformed lines were seeded in M3434 and scored 6–7 days later. RPS6K inhibition studies
were set by adding 3.3 mL DMSO, either as vehicle or with a final concentration of 3.5 mM of
PF4708671 (Tocris), directly to the methylcellulose medium, with mixing prior to cell addition.
Table 1. Antibodies used in flow cytometry analysis and cell sorting.
Antibody Fluorochrome Catalogue # Clone Dilution Supplier
CD45.1 FITC 110705 A20 1:200 BioLegend
CD45.2 AF700 56-0454-81 104 1.:200 Ebioscience
CD45R/B220 (Lin)* Biotin 103204 RA3-6B2 1:300 BioLegend
Ter119 (Lin)* Biotin 116204 Ter119 1:300 BioLegend
Gr1 (Lin)* Biotin 108404 RB6-8C5 1:300 Biolegend
CD3e (Lin)* Biotin 100304 145–2 C11 1:300 BioLegend
CD11b (Lin)* Biotin 101204 M1/70 1:300 BioLegend
CD11b/Mac1 AF700 101222 M1/70 1:200 BioLegend
CD11b/Mac1* PE-Cy7 25-0112-81 M1/70 1:200 Ebioscience
CD16/32/FcgR* PE 101308 93 1:100 BioLegend
CD16/32/FcgR PerCP-Cy5.5 101323 93 1:100 BioLegend
CD34* APC 128612 HM34 1:100 BioLegend
CD34 AF700 560518 RAM34 1:100 BD
CD117/c-Kit* APC-Cy7 105826 2B8 1:50 BioLegend
CD117/c-Kit APC-eF780 47-1171-82 2B8 1:100 Ebioscience
Sca1* PE-Cy7 108114 D7 1:100 BioLegend
Gr1 AF700 108422 RB6-8C5 1:200 BioLegend
Gr1 PB 108430 RB6-8C5 1:100 BioLegend
CD135/Flt3* PE 135305 A2F10 1:100 BioLegend
CD105* PE 562759 MJ7/18 1:100 BD
CD150* Af647 562647 Q38-480 1:100 BD
CD41* Biotin 13-0411-81 eBioMWReg30 1:100 Ebioscience
Streptavidin* BV421 405226 1:200 BioLegend
Streptavidin BV510 405233 1:200 BioLegend
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In vivo analysis of leukemia initiation and engraftment
For analysis of normal hematopoiesis, 106 Kat2a WT or Kat2a KO cKit+ cells were intravenously
injected via tail vein into lethally irradiated (2*5.5Gy) CD45.1 recipient mice. At the described time-
points, BM and Sp were collected and processed into a single-cell suspension for surface marker
staining and flow cytometry analysis. For AML induction, we transplanted 1.5  106 cKit+ Kat2a WT
or Kat2a KO cells transduced with MSCV-MLL-AF9-IRES-YFP, intra-venous into lethally irradiated (2*
5.5Gy) CD45.1 recipient mice. The number of recipients used was determined by the numbers of
cells available post-retroviral transduction and the transduction efficiency estimated by flow cytome-
try at the point of injection, aiming at a minimum of 1 x 105 YFP+ cells/recipient and the same num-
ber of YFP+ cells delivered to all recipients. The investigators were blinded as to the group
allocation, with the injections performed by an investigator not involved in sample preparation, or in
subsequent animal follow-up and tissue collection. Upon signs of illness and following human end-
point criteria, animals were culled, tissue samples collected for histology analysis, and BM and Sp
processed into single-cell suspensions. Flow Cytometry analysis and DNA extraction were per-
formed. Data collection was performed using general identification numbers with no reference to
the experimental group. For limiting-dilution analysis, 5*102 - 5  104 cells from primary leukemia
pooled BM of each genotype were transplanted into sub-lethally irradiated (1*5.5Gy) CD45.1 recipi-
ent mice (3–4/dose and genotype). Numbers of animals used were contingent on availability on
CD45.1 recipients aiming at no less than 10 recipients per genotype divided between 3 cell doses to
allow for limiting dilution statistical analysis.
Retroviral transduction
Retroviral construct MSCV-MLL-AF9-IRES-YFP was previously described (Fong et al., 2015). For viral
particle production, Human Embryonic Kidney (HEK) 293 T cells were seeded at 2.5  106 cells/10
cm dish in DMEM supplemented with 10% Hi-FBS, 2 mg/mL L-Glutamine, 1% PSA and cultured
overnight at 37˚C 5% CO2. The following day, a transfection mix [per plate: 47.5 mL of TranSIT
(Miros), 5 mg of packaging plasmid psi Eco vector (5 mg), retroviral vector (5 mg) and 600 mL of Opti-
mem Medium (Gibco)] was prepared according to manufacturer’s instructions and added dropwise
to cells followed by plate swirling and overnight culture at 37˚C 5% CO2. Medium was replaced with
R20 the next day. At 24 and 48 hr after R20 replacement, medium was collected and filtered through
a 0.45 mM syringe filter, and viral particle suspension medium was added to BM cells. BM cells from
6 to 10 week old Kat2a WT and Kat2a KO mice were collected and Lineage-depleted as described
above (Isolation of mouse BM stem and progenitor cells), and cultured overnight at 37˚C 5% CO2 in
supplemented R20. For viral transduction, BM cells were briefly centrifuged at 400G, 5 min, and viral
particle suspension medium supplemented with 10 ng/mL mIL3, 10 ng/mL mIL6, and 20 ng/mL
mSCF added to a final density of 106 cells/mL. Cells were plated in 6-multiwell plates and centri-
fuged for 1 hr at 2000 rpm, 32˚C. After, cells were incubated for 4 hr at 37˚C 5% CO2. A second
round of viral transduction was performed, with post-centrifugation incubation performed overnight.
Next day, cells were collected, pelleted and washed three times with PBS (2x) and R20 (1x). YFP
level was accessed by Flow Cytometry in a Gallios Analyser (Beckman Coulter).
Establishment of MLL-AF9 transformed cell lines
MLL-AF9 clonal liquid cultures were set up using MLL-AF9 retrovirus-transduced primary BM cells
(see Retroviral Transduction section). Transformed cells enriched in vitro by 3 rounds of serial plating
(CFC assays) were maintained in R20 supplemented on alternate days with mSCF, mIL3 and mIL6, all
at 20 ng/mL. Cells were cultured at 2*105 cells/ml and passaged when they reached a density of
1*106/ml.
Flow cytometry
Cell surface analysis of BM and Sp was performed using a panel of antibodies marked with *
described in Table 1, as per the following sorting strategies: HSC - Lin– cKit+ Sca1+ CD34– Flt3-;
MPP: Lin– cKit+ Sca1+ CD34+ Flt3-; LMPP: Lin– cKit+ Sca1+ CD34+ Flt3+; CMP: Lin– cKit+ Sca1-
CD34+/low CD16/32low; GMP: Lin– cKit+ Sca1+ CD34+ CD16/32high; MEP: Lin– cKit+ Sca1+ CD34-
CD16/32-; Lin-: CD3e- B220- Gr1- CD11b- Ter119-. Data were acquired on Gallios (Beckman Coulter)
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or LSRFortessa (BD) cytometers; data analysis used Kaluza software (Beckman Coulter). Cell sorting
was performed on Influx or AriaII instruments (both from BD).
Measurement of protein synthesis
Six million cells each from the spleens of 3 individual secondary leukemia samples per genotype
were cultured overnight in supplemented R20 to allow recovery after thaw. O-propargyl-puromycin
(OP-Puro, Thermo Fisher Scientific) was added directly to 80% of each culture at a final concentra-
tion of 50 mM and incubated for 1 hr at the end of the culture period; the remainder was treated
with PBS and processed in parallel as a control. After incubation, cells were washed twice in ice-cold
PBS without Ca2+ or Mg2+ (Sigma), and resuspended in PBS/10%FBS for cell surface staining with
Lineage markers (Gr1/Mac1-AF700), c-Kit-APC-ef780, Sca1-PE-Cy7, CD34-APC, CD16/32-PerCP-
Cy5.5 (see Table 1) for 30 min on ice. After washing, cells were fixed in 1% paraformaldehyde (PFA)
in PBS for 15 min on ice, protected from light, washed, and then permeabilized in PBS/3% FBS/0.1%
saponin (permeabilization buffer) at room temperature, in the dark, for 5 min. Cells were washed
and used immediately in the azide-alkyne cyclo-addition reaction with Click-iT Cell Reaction Buffer
Kit (Thermo Fisher Scientific; C10269) and Alexa Fluor 555-Azide (Thermo Fisher Scientific; A20012)
with a master reaction solution freshly prepared as per manufacturer’s instructions for immediate
use. Alexa Fluor 555-Azide was used at a final concentration of 5 mM. The reaction proceeded in the
dark at room temperature for 30 min; cells were washed twice in permeabilization buffer and then
counterstained with DAPI 3.3 mg/ml in PBS for 5 min prior to flow cytometry analysis. We did not
observe any effect of cell cycle status on differential OP-Puro labeling.
Polysomal profiling
MOLM-13 cells (ID: CVCL_2119) were grown to an approximate density of 1  106 cells/mL, treated
with cycloheximide (100 mg/mL) for 15 min, washed in ice-cold PBS and stored at  80˚C. Cells were
lysed in buffer A (20 mM HEPES pH 7.5, 50 mM KCl, 10 mM (CH3COO)2 Mg, EDTA-free protease
inhibitors (Roche), supplemented with cycloheximide 100 mg/mL, 1 mM PMSF, 100 U/mL RNase
inhibitor (Promega), 1% (vol/vol) sodium deoxycholate, and 0.4% (vol/vol) NP-40) at 108 cells/mL for
10 min on ice. Lysates were cleared by centrifugation (8000 g for 5 min at 4˚C) and 3 A254nm units
loaded onto a 10–50% (wt/vol) sucrose gradient in buffer A in Polyallomer 14  95 mm centrifuge
tubes (Beckman). After centrifugation (Beckman SW40Ti rotor) at 260 900 g for 3 hr at 4˚C, gradients
were fractionated at 4˚C using a Gilson Minipulse three peristaltic pump with continuous monitoring
(A254nm). Samples were analysed using a Brandel gradient fractionator, the polysome profiles were
detected using a UV monitor (UV-1, Pharmacia) at A254, and 0.5 mL fractions were collected. The
electronic outputs of the UV-1 monitor and fraction collector were fed into a Labjack U3-LV data
acquisition device with an LJTick-InAmp preamplifier.
Quantitative real time PCR (Q-RT-PCR)
Total RNA was extracted using Trizol Reagent (Invitrogen). RNA from equal numbers of cells was
reverse-transcribed using Superscript II (Invitrogen), following manufactures’ instructions. Comple-
mentary (c)DNA was analyzed in duplicate or triplicate by qPCR using Taqman gene expression
assays (Ppia; Mm03024003_g1; Hprt: Mm01545399_m1; Kat2a: Mm00517402_m1) and Taqman
Gene Expression Mastermix (Applied Biosystems). Gene expression levels were determined by the
Pfaffl method following normalization to Reference gene, as stated. For exon 2–18 in-frame prod-
ucts, qPCR using Sybr Green Master Mix (Applied Biosystems) was performed in triplicates. Primers
used were: Kat2a Exon 1–2 (forward: GTCTTCTCAGCTTGCAAGGCC, reverse: AAAGGGTGCTCA-
CAGCTACG); Kat2a Exon2-18 (forward: GTAGCTGTGAGCACCCTTTGG, reverse: TTCGCTGTC
TGGGGGATTGT); Kat2a Exon18 (forward: CTCATCGACAAGTAGCCCCC; reverse: GTCCCTGGC
TGGAGTTTCTC).
Single-cell RT-PCR
MLL-AF9 secondary leukemia cells from Kat2a WT and KO backgrounds were freshly thawed,
stained with Lin cocktail, c-Kit-APC-ef780, Sca1-PE-Cy7, CD16/32-PerCP-Cy5.5, CD34-AF700 and
Streptavidin BV510 (see Table 1), plus dead cell exclusion with Hoechst 32558 (Thermo Fisher Scien-
tific), sorted as Lin-c-Kit+Sca1-CD16/32+ and single-cell deposited into 96-well plates containing 3 ml/
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well of 0.67% NP-40 and 2U of RNasin Plus (Promega) in RNase-free water. Plates were vortexed
after deposition, centrifuged for lysate collection, and frozen immediately in dry ice. Plates were
stored at  80˚C. Upon thaw, cDNA was synthesized from the single-cell lysates using 5U Superscript
II (Invitrogen) and 1 mM each of gene-specific primers for Hprt and Kat2a (outer reverse, Table 2) in
a 10 ml reaction mix as per the manufacturer’s protocol (42˚C, 1 hr; 70˚C inactivation, 15 min). The
total cDNA reaction was used in a 50 ml first round PCR with duplexed outer forward primers for
Hprt and Kat2a at a final concentration of 200 nM and 1.25U HotStar Taq (Qiagen) in a reaction mix
as per manufacturer’s protocol. Cycling conditions: 95˚C, 15 min; 40*(94˚C, 1 min; 60˚C, 1 min; 72˚C,
2 min); 72˚C, 5 min; 25˚C, 30 s. Two ml of the first-round product were amplified in each of two sepa-
rate second round PCR using nested primers for the two individual genes (Table 2). Reaction mixes
as per the first round PCR, but in a final volume of 25 ml. Cycling conditions: 95˚C, 15 min; 40*(94˚C,
30 s; 60˚C, 1 min; 72˚C, 1 min); 72˚C, 5 min; 25˚C, 30 s. Second-round products were run in a 2% aga-
rose TAE1x gel at 50V, 1 hr, stained for 45–60 min in SYBRSafe solution (Thermo Fisher Scientific) in
double-distilled water, and DNA visualized on a BioRad Imager.
Chromatin immunoprecipitation (ChIP)
Pools of total BM cells from MLL-AF9 Kat2a WT and Kat2a KO primary leukemia samples (ChIP-
sequencing) and of total BM or spleen cells from MLL-AF9 Kat2a WT and Kat2a KO secondary leuke-
mias (ChIP-qPCR) were crosslinked with 1% Formaldehyde Solution (Sigma Aldrich) for 10 min at
room temperature (RT), with gentle rotation (50 rpm). Fixation was stopped with Glycine, and cells
incubated for 5 min, RT, with gentle rotation (50 rpm), followed by two washing steps in ice-cold
PBS. Cell pellets were resuspended in Lysis buffer (20 mM Hepes pH 7.6, 1% SDS and 1/100 Prote-
ase Inhibitors cocktail (PIC, Sigma Aldrich) followed by Nuclei preparation. Chromatin pellets were
sheared in a Bioruptor Pico Plus (Diagenode) in TPX tubes, using 3 runs of 11 cycles (Cycle: 30 s ON
30 s OFF) on high setting. A short spin was performed between runs and samples were transferred
to new TPX tubes. 2–10% of total sheared chromatin was kept for input reference. Immunoprecipita-
tion was set up using Dilution Buffer (0.15% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH8
and 167 mM NaCl), PIC, and the respective antibody (Table 3) and the sheared chromatin incubated
overnight at 4˚C with rotation. On the following day, protein A/G magnetic beads were pre-cleared
with Dilution Buffer supplemented with 0.15% SDS and 0.1%BSA, then mixed with immunoprecipita-
tion mix and incubated for at least 4 hr at 4˚C with rotation. Chromatin-Antibody-Beads mixes were
sequentially washed with ChIP Wash1 (2 mM EDTA, 20 mM Tris pH8, 1% Triton X-100, 0.1% SDS
and 150 mM NaCl), ChIP Wash2 (2 mM EDTA, 20 mM Tris pH8, 1% Triton X-100, 0.1% SDS and 500
mM NaCl), ChIP Wash3 (1 mM EDTA and 10 mM Tris pH8) and captured on a magnetic rack. Cap-
tured beads were incubated for 20 min with rotation in freshly prepared Elution Buffer (1% SDS and
0.1M NaHCO3). Supernatants were collected and decrosslinking performed overnight. DNA was col-
umn-purified using DNA clean and concentrator TM 5 KIT (Zymo Research), according to manufac-
turer’s instructions, using 20 mL Zymo Elution Buffer. DNA quality control was performed using DNA
Qubit 2.0/3.0 (Invitrogen); DNA fragment size <500 bp (typically 200–300 bp) was confirmed by gel
electrophoresis of input material on a 1.5% agarose/TAE gel.
For ChIP-qPCR, eluted DNA samples were diluted 3–5 times and tested by SYBR green qPCR
(primer sequences in Table 4) using 2 ml diluted DNA per triplicate reaction. Peak enrichments were
quantified by the  2DDCt method relative to mouse IgG (Gabpa ChIP) or rabbit IgG (Myc ChIP), using
the intergenic region in mouse chromosome 1 (mChr1) as a reference. Duplicate to quadruplicate
ChIP experiments were analyzed. For ChIP-sequencing analysis of histone modifications, DNA from
duplicate immunoprecipitation experiments and the respective input material underwent library
Table 2. Primers used for single-cell RT-PCR analysis.
Forward Reverse
Hprt (outer) GGGGGCTATAAGTTCTTTGC TCCAACACTTCGAGAGGTCC
Hprt (nested) GTTCTTTGCTGACCTGCTGG TGGGGCTGTACTGCTTAACC
Kat2a (outer) CTTCCGCATGTTTCCCACTC GATGTCTTTGGAGAAGCCCTG
Kat2a (nested) GGAAATCGTCTTCTGTGCCG TTTGGAGAAGCCCTGCTTTTTG
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preparation with the NextFlex Rapid DNA kit (12 cycles) at the MRC/WT Cambridge Stem Cell Insti-
tute Genomics Core Facility. After quality control, libraries were sequenced on an Illumina HiSeq
4000 sequencer at the CRUK Cambridge Research Institute, using 50bp-single-end sequencing.
ChIP-seq data analysis
Raw ChIPseq reads were analyzed on the Cancer Genomics Cloud (CGC) platform (Lau et al.,
2017). Reads were aligned to the mm10 mouse genome using the Burrows-Wheeler Aligner (BWA).
Peaks from aligned reads were obtained using MACS2 peak calling algorithm with a significance
q-value of 0.05. The deepTools bamCoverage command (Ramı´rez et al., 2016) was used to deter-
mine reads enrichment relative to input; only ChIP-seq samples with clear separation from control
were retained, with exclusion of one H3K4me1 and one H3K27ac replicate; consensus peaks were
used for duplicate samples. To analyze changes in acetylation patterns at promoters and enhancers,
H3K4me3 and H3K4me1 peaks respectively, were crossed with H3K9ac-only, H3K27ac-only and dual
acetylation peaks from the corresponding genotypes. H3K9ac-only peaks associated with me3 were
used for further analysis. Genomic peaks were obtained for Kat2a WT and Kat2a KO genotypes sep-
arately using Bedtools intersect (Quinlan and Hall, 2010) and H3K4me3 K9ac peaks exclusive to WT
retained as putative Kat2a peaks. Peak locations were converted to fastq sequences using UCSC
table browser tool (Karolchik, 2004). Genomic Regions Enrichment of Annotations Tool, GREAT
(McLean et al., 2010) was used to assign gene identities to the fastq sequences associated with
putative Kat2a peaks, with gene promoter peaks called within - 1 kb to + 500 bp of the transcription
Table 3. Antibodies used in chromatin immunoprecipitation (ChIP).
Antibody Catalogue# Supplier
H3K27ac Ab4729 Abcam
H3K9ac 07–352 Millipore
H3K4me3 Ab8580 Abcam
H3K4me1 Ab8895 Abcam
Myc sc-764 x Santa Cruz Biotechnology
Gabpa sc-28312 Santa Cruz Biotechnology
rabbit IgG 12–370 Millipore
mouse IgG sc-2025 Santa Cruz Biotechnology
Table 4. Primers used for ChIP-quantitative PCR analysis.
Forward Reverse
Arpc3 GTGCGTTTATTCCTTCCGCC TCGAATGCTTACCGGCATCT
Cct4 TGGTCTCGTTTGCAGCTTTC TGCAGGAGACGAACTAAGGA
Cct7 AACGCTCACATCCTCCGTT GTAGGCACAACCTGACAACC
Clptm1l GTAGGCACAACCTGACAACC GGGTAACAAGAGAGCAGCAGA
Eif4e GCAGACCACATCAACGACTCT TCTTTTCGCCTCCCACCATT
Gadd45g GGCATCGACTCTGACCTTGT CGCTATGTCGCCCTCATCTT
Kdelr2 CCTTGAGTGTGGCCGTCTAA TCAATGGTGACGTGGAGCAA
mChr1 (intergenic) CATAGATGAAGCTGCCACATAGGT GTGGGCAAGGACAAAGCATTA
Parl CTTCGCCAGGCTCAATCTCA ATACACACCAAGGGGCCTGA
Pcbp1 AGAGCGCCTTGTGCTTTCTT CTGGTCCTTTCGGCCAAGTA
Ralbp1 GTGTTGACTTGCGGGAAACT GCGGCTTTAACTCGGGTATG
Rps15 TCCGCAAGTTCACCTACCGT TCTGGCTCTATTTCCAGCACC
Rps7 GCTTAGAAAGAGGGACGGCT CGGTTTCCACCCACCTACTT
Zbtb8oS ATCACCCGTTCTTCCACTGC AGGTTTGTGCCCTTTCCGTT
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start site (TSS). We used ENCODE ChIP-Seq Significance Tool (Auerbach et al., 2013) to obtain
putative transcription factor binding, including identification of genes bound by GCN5/KAT2A, to
confirm the identity of putative Kat2a targets.
Single-cell RNA sequencing and data analysis
Terminal BM samples from Kat2a WT and Kat2a KO MLL-AF9 primary leukemia animals were col-
lected (WT - 5; KO - 4) and the individual cell samples stored at  150˚C. Cells were thawed and
pooled for library preparation. Specifically, 12K live cells per genotype pool were sorted on an Influx
sorter (BD) on the basis of YFP expression (reporting MLL-AF9), Hoechst 32258 exclusion (live cells)
and singlet configuration (pulse width) and used for library preparation with Chromium Next GEM
Single Cell 3’GEM, Library and Gel Bead Kit v1 (10XGenomics) aiming at 6K single cells per sample.
Library preparation and single-end sequencing on a NextSeq 500 sequencer were done at CRUK
Cambridge Research Institute. Raw single cell RNAseq fastq reads were analysed using Cellranger
software (v2.1.1) to obtain the cell-gene count-matrix. Seurat (Butler et al., 2018) was used for pre-
processing the count-matrix data and obtaining differential gene expression between the two geno-
types. We employed pairwise distance between gene correlations as a measure of cellular heteroge-
neity as described (Mohammed et al., 2017), by identifying the top 500 highly variable genes in
both Kat2a WT and KO genotypes based on distance-to-median (DM) and calculating Spearman cor-
relation coefficients between all gene pairs. The correlation matrix was used to compute the pairwise
distance measure. RaceID/StemID (Gru¨n et al., 2016) algorithms were used for clustering using
t-SNE and obtaining pseudo-temporal arrangement of clusters based on entropy information and
cluster stem scores. Monocle version 2.6.4 (Trapnell et al., 2014) was used as an alternative pseudo-
time analysis for Kat2a WT and Kat2a KO cells. The relative cell state ordering in Monocle was unsu-
pervised, with leukemia self-renewal Hoxa9 expression employed to determine the directionality of
the trajectory. Parameters for the stochastic gene expression were fitted to the two-state promoter
model using the D3E algorithm (Delmans and Hemberg, 2016) with the Bayesian method option
for model fitting. Global normalized data were used in the Robust gene set analysis; cluster-specific
parameter derivation included computation of cluster-specific normalization. A multiple linear
regression of CV and average gene expression with respect to burst size and burst frequency for
Kat2a WT and Kat2a KO cells were performed using lm() function in R statistical package. P-values
for significant coefficients were calculated as a output of the lm() function. Scripts for integration of
single-cell RNA-seq and ChIP-seq data were coded in R Language (version 3.4.4) and are provided
with this submission. Gene Ontology analysis was performed with the PANTHER online tool
(Mi et al., 2019), selecting binomial analysis with Bonferroni correction. Gene sets were obtained
from the Molecular Signatures Database (MSigDB) (Subramanian et al., 2005) to plot gene signa-
tures on tSNE plots. The self-renewal gene signature associated with MLL leukemia, GCM_MLL, was
employed in Figure 4—figure supplement 1A. For Figures 6A and 4 gene sets (MORF_EIF4E,
MORF_EIF3S2, MORF_EIF4A2 and MORF_EIF3S6) were pooled to represent a translation-associated
gene signature.
Statistical analysis
Statistical tests performed are specified in the figure legends. Differences were obtained with signifi-
cant p-value<0.05. Analyses were performed in statistical language R (version 3.4.4) or using Prism
version 8.1.2 (GraphPad).
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